478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?. (23rd October 2018) - Mata Velasco, E; González-Flores, E; Juez Martel, I; Alonso, V; Iranzo Gomez, P; Martinez Lago, N; Lopez, C; Cabrera Romero, J M; Safont Aguilera, M J; Ruiz Casado, A; Salgado Fernandez, M; González Astorga, B; et al.